England’s Innovative Medicines Fund Needs De-Risking To Make It Work

The Innovative Medicines Fund is not delivering the ambition that was set out when it was launched in England last year, according to one UK company general manager.

Pound Blister Pack
England's Innovative Medicine's Fund Needs To Be Improved • Source: Shutterstock

Some eight months after its launch, companies are still not using England’s £340m ($407m) Innovative Medicines Fund (IMF) to get their new non-cancer drugs to patients because it carries too much risk, says Sean Richardson, vice-president and general manager for the UK and Ireland at Alexion Pharmaceuticals Inc..

Launched in June 2022, the IMF was designed to offer conditional reimbursement for innovative new non-cancer drugs that are associated...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography